Cancer / Oncology/Pancreatic cancer
Gastrointestinal · type
Pancreatic cancer
Clinical / Scientific
PDAC is defined by KRAS mutation in most cases, plus CDKN2A, TP53 and SMAD4 losses, intense desmoplasia, , dependence and immune exclusion. Core pathway maps were shown by global genomic analyses. Stromal and metabolic adjuncts are mechanistically salient; they are not substitutes for oncology care.
Core Biological Drivers
KRAS
Near-universal initiating .
CDKN2A / TP53 / SMAD4
Sequential suppressor loss.
Desmoplastic stroma
CAF/TGF-β compression.
Autophagy dependence
Nutrient scavenging in a harsh matrix.
Key Pathways
Scientific explanation
RAS GTPases and RAF kinases are frequent oncogenic nodes. KRAS, NRAS and BRAF mutations lock mitogenic signalling on in a ligand-independent way in many tumours.
Scientific explanation
The RAS–RAF–MEK–ERK cascade transmits mitogenic RTK signals to programmes for proliferation and differentiation.
Scientific explanation
phosphorylates PIP2 to PIP3, recruiting . supports growth, survival, glucose uptake and mTORC1 input. Pathway activation is common via PIK3CA mutation, PTEN loss or -tyrosine- signalling.
Scientific explanation
TGF-β is cytostatic in intact epithelium but later supports , immune suppression and stromal . Context switches its role during progression.
Scientific explanation
recycles organelles and can support survival under nutrient or therapy stress. Context determines tumour-suppressive versus therapy-protective roles.
Scientific explanation
Aerobic (Warburg metabolism) supports ATP, biomass and redox buffering even when oxygen is available. Hexokinase, PKM2 and lactate export are frequent nodes.
Scientific explanation
Glutamine supplies nitrogen and anaplerotic carbon via glutaminase and glutamate dehydrogenase, supporting nucleotide synthesis and TCA replenishment in MYC-driven and other tumours.
Scientific explanation
-inducible factors stabilize when oxygen is low, shifting toward , and survival.
Scientific explanation
family ligands drive endothelial sprouting and vascular permeability, a canonical tumour axis.
Scientific explanation
PD-1 on T cells engaging PD-L1/PD-L2 restrains cytotoxic function. Tumour or myeloid PD-L1 is a canonical adaptive immune-evasion axis.
Scientific explanation
Epithelial–mesenchymal plasticity, driven by TWIST/SNAIL/ZEB and TGF-β/Wnt/Notch inputs, reduces adhesion and increases motility and stem-like features.
Scientific explanation
Stem-like programmes (Wnt, Notch, Hedgehog, ALDH, CD44) can support self-renewal, quiescence and therapy tolerance in a minority population.
Scientific explanation
Hippo signalling restrains YAP/TAZ transcriptional co-activators. NF2 loss, common in mesothelioma, derepresses YAP-driven growth programmes.
Pathway Convergence
Target → pathway → downstream effect → biological consequence. Shared intersections are mechanistic maps, not protocols.
Growth-factor signalling
Ligand or mutation-driven RTK input feeds PI3K/AKT and mTORC1, supporting anabolic growth. This is a map of signalling, not a treatment protocol.
Hypoxia to vessels
Low oxygen stabilizes HIF-1α, inducing VEGF and endothelial sprouting. Anti-angiogenic pharmacology intersects this axis but does not erase the tumour ecosystem.
Stroma and TGF-β
Desmoplastic stroma and TGF-β can compress vessels and exclude T cells. Stromal adjuncts aim at the neighbourhood, not at a single oncogene.
Energy stress
Energetic stress activates AMPK, which can restrain mTORC1. Biguanides and related tools map onto this axis in models.
Metabolic Vulnerabilities
Aerobic supports ATP, biomass and acidification even when oxygen is available. Extent varies by tumour and remains a vulnerability hypothesis rather than a uniform target.
Glutamine anaplerosis and nucleotide nitrogen demand are prominent in MYC-high and rapidly proliferating tumours. Dependence is heterogeneous.
Macropinocytosis and scavenge extracellular protein in KRAS-PDAC models.
Tumor Microenvironment
Cancer-associated fibroblasts, TGF-β and extracellular-matrix stiffness can compress vessels and exclude T cells, especially in desmoplastic tumours.
Disordered vasculature creates , HIF-1α stabilization, induction and immune-suppressive adenosine/lactate milieus.
Tumour-associated macrophages and myeloid-derived suppressor cells secrete cytokines that support invasion and blunt cytotoxic T cells.
Metastasis Module
, protease-mediated invasion, , circulating tumour-cell survival and organ-specific colonization form the metastatic cascade. Pre-metastatic niches and vascular permeability influence tropism.
Resistance Biology
Stromal drug exclusion, KRAS persistence, -mediated survival and .
Cancer Stemness
Wnt, Notch, Hedgehog, ALDH and CD44-associated programmes can mark stem-like fractions with quiescence and therapy tolerance. These markers are not interchangeable across tumour types.
Mechanism-Based Adjunctive Strategies
Compounds appear only where a mechanistic overlap exists for this cancer. Evidence tiers are not equivalent. Nothing here is a treatment recommendation.
Losartan
Target / Mechanism
AT1- . In desmoplastic models, angiotensin blockade can reduce TGF-β-linked stromal compression and improve perfusion; this is adjunctive stromal biology, not cytotoxic oncology.
Cancer relevance
AT1 blockade can reduce TGF-β-linked desmoplasia and improve perfusion in models, notably pancreatic. Stromal decompression is not cytotoxicity.
Stroma / perfusion adjunctive research. Convergence: TGF-β, Angiogenesis.
Candesartan
Target / Mechanism
ARBs share AT1-blockade biology with losartan. Tumour- hypotheses are class-level and not tumour-type-proven treatments.
Cancer relevance
ARBs share AT1-blockade stromal hypotheses with losartan. Class-level biology is not tumour-type-proven treatment.
Stroma / TGF-β class-level research. Convergence: TGF-β, Angiogenesis.
Target / Mechanism
Lysosomotropic agent that raises endosomal/autophagosomal pH, impairing flux. Combination trials in oncology have been mixed; blockade is not equivalent to proven benefit.
Cancer relevance
Lysosomal pH elevation impairs flux. Early combination trials exist; benefit is not established and toxicity/retinal risk remain labelled concerns.
Autophagy-modulation research combinations. Convergence: Autophagy.
Target / Mechanism
Modest complex I inhibition raises AMP:ATP, activating and restraining hepatic and -linked anabolism. Direct antineoplastic efficacy is not established from that pharmacology alone.
Cancer relevance
activation and restraint provide a metabolic rationale in - and -linked tumours. Human data are mixed and do not establish metformin as cancer therapy.
Metabolic adjunctive research context. Convergence: AMPK, mTOR, Glycolysis.
Target / Mechanism
Benzimidazole that binds β-. Mammalian disruption, mitotic arrest and related signalling in cancer models are preclinical and are not an approved anticancer use.
Cancer relevance
disruption can trigger mitotic stress and in cell and animal models. This is not an established oncology use.
Experimental antimitotic / microtubule stress. Convergence: Apoptosis, p53.
Target / Mechanism
uncoupler in cestodes; mammalian models report , Wnt/β-catenin and modulation. Those host-signalling findings are investigational/preclinical.
Cancer relevance
Models report Wnt/β-catenin, and effects. Host signalling findings remain investigational.
Wnt / STAT3 signalling models. Convergence: Wnt/β-catenin, JAK/STAT, mTOR.
Curcumin
Target / Mechanism
Polyphenol with promiscuous in-vitro NF-κB, and ROS effects. Bioavailability is poor; dish activity does not establish clinical anticancer efficacy.
Cancer relevance
In-vitro NF-κB/ effects are frequent. Poor bioavailability and absence of robust clinical anticancer efficacy keep this pathway-level.
Inflammatory-signalling dish models. Convergence: NF-κB, JAK/STAT.
Disulfiram
Target / Mechanism
ALDH ; copper-complexed forms can inhibit proteasome and NF-κB-related survival programmes in models. Clinical oncology evidence remains limited.
Cancer relevance
ALDH and copper-dependent proteasome/NF-κB stress in models; clinical oncology remains limited.
ALDH / redox experimental context. Convergence: Cancer stemness, NF-κB, Oxidative stress.
Target / Mechanism
Tetracycline antibiotic that can inhibit matrix metalloproteinases and, at experimental exposures, protein synthesis. Oncology uses remain investigational.
Cancer relevance
MMP inhibition and experimental effects map to invasion and stem-like states in models.
Anti-invasive / mitochondrial experimental context. Convergence: Invasion, Cancer stemness, Mitochondrial oxidative phosphorylation.
Berberine
Target / Mechanism
Isoquinoline alkaloid that can inhibit complex I and activate in metabolic models, with additional -independent reports. Not an approved antineoplastic.
Cancer relevance
Complex I / pharmacology overlaps metformin-like energy stress in models. Bioavailability and lack of oncology indication keep this mechanistic.
Metabolic energy-stress hypothesis. Convergence: AMPK, mTOR, Mitochondrial oxidative phosphorylation.
Research Context
- Pancreatic pathways. Jones S, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801-1806. https://doi.org/10.1126/science.1164368
- Warburg. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-1033. https://doi.org/10.1126/science.1160809
- Hallmarks. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. https://doi.org/10.1016/j.cell.2011.02.013
- Resistance. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714-726. https://doi.org/10.1038/nrc3599
This oncology atlas is educational. Pathway maps, adjunctive strategies, and compound listings describe mechanistic relevance. They do not establish clinical efficacy, do not recommend treatment, and are not a substitute for oncology care. Evidence tiers are not equivalent.